Warren Buffett Detailed Fundamental Analysis

Validea's guru fundamental report indicates that Accenture PLC (ACN) receives an 86% rating based on their Patient Investor model, which is based on Warren Buffett's investment strategy. The strategy favors firms exhibiting long-term, predictable profitability, low debt, and reasonable valuations, all criteria which ACN currently meets. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Analysis

Accenture PLC (ACN), a large-cap growth stock operating within the Computer Services industry, demonstrates compelling fundamental strength according to Validea's Patient Investor model, which is based on Warren Buffett's investment philosophy. The company achieved an 86% rating, signifying notable interest from this strategy, which seeks firms with long-term predictable profitability, low debt, and reasonable valuations. ACN favorably meets all tested criteria of this model, including earnings predictability, debt service, return on equity, return on total capital, free cash flow generation, use of retained earnings, share repurchase activity, initial rate of return, and expected return. This robust performance across multiple fundamental metrics, coupled with a strongly positive sentiment score specific to ACN (0.85), underscores the company's solid financial health and alignment with value-oriented investment principles.

Key Decisions for Investors

• Investors adhering to a long-term, fundamentally-driven approach should consider ACN's strong alignment with the Patient Investor model, particularly its predictable profitability and low debt profile.
• The company's successful performance across all key financial metrics, including robust free cash flow and return on equity, suggests ACN could be a resilient holding for quality-focused growth portfolios.
• Prospective and current investors should continuously assess ACN's valuation to ensure it remains within a reasonable range, as significant price appreciation could alter its attractiveness under the Patient Investor strategy's criteria.